Search

Your search keyword '"Thankamony, Priyakumari"' showing total 153 results
Start Over Author "Thankamony, Priyakumari"
153 results on '"Thankamony, Priyakumari"'

2. Optimizing the Outcome of Pediatric Metastatic Neuroblastoma in a Nontransplant Setting in a Developing Country: Retrospective Study from a Tertiary Cancer Center in India.

Author

Nair, Manjusha, R., Prasanth V., Thankamony, Priyakumari, Rajeswari, Binitha, S., Guruprasad C., and George, Preethi Sara

Subjects
LACTATE dehydrogenase, OVERALL survival, BONE marrow, PROGRESSION-free survival, DEVELOPING countries
Abstract

Objective This article estimates the survival of children over 1 year of age diagnosed with metastatic neuroblastoma (NB) and treated in a nontransplant facility and determines the factors affecting survival. Materials and Method Case records of children aged 1 to 14 years treated for metastatic NB in our center from January 2008 to December 2017 were studied. Patients received conventional chemotherapy followed by surgery, radiotherapy, and metronomic maintenance chemotherapy. Results Eighty-nine patients with metastatic NB received treatment. Mean age was 3.5 years and male:female ratio was 1.1:1. The most common primary site was suprarenal (55%) and the most common site of metastasis was bone marrow (76%). Forty percent patients had multiple metastatic sites. Mean baseline lactate dehydrogenase (LDH) was 3724 U/L (range 303–16609 U/L) and 65% patients had LDH > 750 U/L. Fifty-three patients (59.6%) had good response to chemotherapy as evidenced by clearance of metastatic disease, but out of them, 43 patients (81%) progressed subsequently. Twenty-six patients underwent surgery and 12 patients received maintenance therapy. Seventy-four patients (86%) developed recurrence and all but one died. Median time to recurrence and death were 9 months (range 0–120 months) and 10 months (range 1–123 months), respectively. At a median follow-up of 72 months (range 15–135 months), 16 patients are alive, with 5-year disease-free survival and overall survival of 17.6 and 18.4%, respectively. Age, baseline LDH, chemotherapy regimen, and response to treatment significantly affected survival. Conclusion Younger age, lower baseline LDH, and good response to chemotherapy appear to confer survival advantage in pediatric metastatic NB, and may be used for optimization of treatment in the nontransplant setting in developing countries. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

4. Older age, CNS leukaemic involvement and induction tumour lysis increases the risk of methotrexate (MTX)‐induced neurotoxicity in childhood acute lymphoblastic leukaemia/lymphoma: Experience from a tertiary care centre in South India.

Author

Rupakumar, Thirumala, Sankar, Ajay, Vijayasekharan, Kalasekhar, Varikkattu Rajendran, Prasanth, Chellapan Sojamani, Guruprasad, Rajeswari, Binitha, Nair, Manjusha, Anandarajan, Rakesh, Dennis, Divya, and Thankamony, Priyakumari

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, CENTRAL nervous system tumors, TUMOR lysis syndrome, NEUROTOXICOLOGY, METHOTREXATE, TERTIARY care
Abstract

Summary: Methotrexate (MTX), although an indispensable part of contemporary treatment protocols for childhood acute lymphoblastic leukaemia (ALL)/lymphomas (LBL) in improving outcomes, can lead to serious neurotoxicity with long‐term consequences. The aetiopathogenesis, predisposing factors and treatment for MTX‐induced neurotoxicity are not yet well defined. The aim of our study was to detect the incidence, risk factors and to assess the overall outcomes of MTX‐induced neurotoxicity among large cohort of paediatric ALL/LBL patients treated on a uniform protocol. We conducted retrospective audit of medical records of 622 consecutive children (≤14 years) diagnosed with ALL and LBL between January 2018 and December 2022 and treated on modified BFM‐95 protocol at the Department of Pediatric Oncology, Regional Cancer Centre, Thiruvananthapuram. Risk factors predisposing to MTX‐induced neurotoxicity were identified using binary logistic regression analysis. Forty‐three children were diagnosed with MTX‐induced neurotoxicity with an incidence rate of 6.9%. More than two‐thirds of them had high‐grade MTX‐induced neurotoxicity CTCAE v5.0 with a median age of 9 years (range: 9 months to 14 years). Almost half of them developed MTX neurotoxicity during Protocol M followed by Phase‐Ib consolidation (15%). Majority of these patients (84%, 36/43) were challenged again with MTX, with 11% (4/36) developing recurrence. Fifteen per cent had persistent neurological deficits at last follow‐up. Univariate analysis found older age (age > 5 years) (p < 0.001), T‐cell phenotype (p = 0.040), tumour lysis syndrome during induction (p < 0.001), baseline renal problems prior to MTX exposure (p < 0.001) and CNS leukaemic involvement (p < 0.003) to be significantly associated with MTX neurotoxicity. On multivariate analysis, older age (>5 years), tumour lysis during induction and CNS leukaemia retained statistical significance (p < 0.05). Methotrexate‐induced neurotoxicity during paediatric acute lymphoblastic leukaemia/lymphoma therapy is a transient phenomenon in majority and re‐challenge with MTX is generally safe. Older age children who develop tumour lysis during induction and CNS leukaemic involvement are at increased risk for MTX‐induced neurotoxicity during ALL/LBL treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. An Assessment of Childhood Cancer Care Services in India- Gaps, Challenges and the Way Forward

Author

Nath, Anita, primary, Mathur, Prashant, additional, Sudarshan, Kondalli Lakshminarayana, additional, Rajput, Gurpreet Kaur, additional, Mascarenhas, Leena, additional, Arora, Ramandeep Singh, additional, Seth, Rachna, additional, Dixit, Sanjeev Kumar, additional, Chinnaswamy, Girish, additional, Banipal, Raja Paramjeet Singh, additional, Bhutia, Tseten, additional, Bodal, Vijay Kumar, additional, Budukh, Atul, additional, Choudhary, Narendra Kumar, additional, C.R, Vijay, additional, Das, Deepshikha, additional, Gundeti, Sadashivudu, additional, Harris, Caleb, additional, Hazarika, Munlima, additional, Jondhale, Sunil Natha, additional, K, Gunaseelan, additional, Khamo, Vinotsole, additional, Kojengbam, Ratan, additional, Kumar, Arun, additional, Majumdar, Saroj Kumar Das, additional, Majumdar, Gautam, additional, Malik, Shikha, additional, MANDAL, SYAMSUNDAR, additional, Najmi, Arshad Manzoor, additional, Kumar, Chandra Mohan, additional, Pandey, Awadhesh Kumar, additional, Pandya, Shashank, additional, Pareek, Puneet, additional, Pautu, Jeremy, additional, Rao, V. Surya, additional, Ramesh, C, additional, Rawal, Manoj, additional, Radhakrishnan, Nita, additional, Radhakrishnan, Venkatraman, additional, Shah, Anand, additional, Singh, S. B., additional, Singh, Varinder, additional, Singh, Pritanjali, additional, Sundriyal, Deepak, additional, Swaminathan, Rajaraman, additional, T, Avinash, additional, Thankamony, Priyakumari, additional, Tawsik, Sopai, additional, and Tiwari, Lokesh, additional

Published
2023
Full Text
View/download PDF

16. Higher incidence of syndrome of inappropriate antidiuretic hormone secretion during induction chemotherapy of acute lymphoblastic leukemia in indian children

Author

Seetharam, Shwetha, Thankamony, Priyakumari, Gopakumar, Kaduveettil, and Krishna, K.

Subjects
Pediatric research, Childhood leukemia -- Drug therapy -- Physiological aspects, Chemotherapy -- Complications and side effects -- Usage, Paraneoplastic syndromes -- Risk factors -- Statistics, Acute lymphocytic leukemia -- Drug therapy -- Physiological aspects, Lymphocytic leukemia, Asians, Cancer research, Hormones, Antineoplastic agents, Pediatrics, Videocassette recorders, Vasopressins, Vincristine, Pituitary hormones, Children, Health
Abstract

Byline: Shwetha. Seetharam, Priyakumari. Thankamony, Kaduveettil. Gopakumar, K. Krishna BACKGROUND: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a well-known adverse effect of vincristine (VCR). Literature suggests that Asians are [...]

Published
2019

24. Outcomes of pediatric mixed phenotype acute leukemia treated with lymphoid directed therapy: Analysis of an institutional series from India

Author

Seetharam, Shwetha, primary, Thankamony, Priyakumari, additional, Gopakumar, Kaduveettil Gopinathan, additional, Nair, Rekha Appukuttan, additional, Jacob, Priya Mary, additional, Jagathnath Krishna, K. M., additional, Rajeswari, Binitha, additional, Nair, Manjusha, additional, Guruprasad, C. S., additional, and Prasanth, V. R., additional

Published
2021
Full Text
View/download PDF

26. High dose methotrexate containing regimen in pediatric non-metastatic extremity osteosarcoma patients: experience from a tertiary cancer center in India.

Author

Rajeswari, Binitha, Guruprasad, Chellapan Sojamani, Nair, Manjusha, Prasanth, Varikkattu Rajendran, Sugath, Bhaskar Subin, and Thankamony, Priyakumari

Subjects
PATIENTS' attitudes, METHOTREXATE, LIMB salvage, OSTEOSARCOMA, CHILD patients, PEDIATRIC oncology
Abstract

Methotrexate containing chemotherapy is less commonly used for treatment of osteosarcoma in resource limited settings. We present our experience with the administration of high dose methotrexate (HDMTX) containing chemotherapy over a period of three years. Children between 1 and 14 years of age with newly diagnosed nonmetastatic extremity osteosarcoma, registered in Pediatric Oncology Department of a tertiary care cancer center in South India between 1st January 2016 and 31st December 2018 and receiving MAP chemotherapy were included. Patients in this study received HDMTX at 12 g/m2. Twenty two patients were included. After neoadjuvant chemotherapy, 20 patients underwent surgery (limb salvage surgery in 16, amputation in 4). The median time from initiation of chemotherapy to surgery was 97.5 days. Eighteen of 22 patients (81.8%) completed planned chemotherapy in our cohort, one patient was lost to follow up after progression and three patients required change of chemotherapy due to toxicities. Of a total of 227 cycles of HDMTX infusions in 22 patients, delayed clearance occurred in 22 cycles (9.7%). Major toxicities were myelosuppression (30 episodes in 17 patients), blood stream infections (24 episodes in 15 patients) and mucositis (15 episodes in 10 patients). Hearing loss was documented in 7 patients. There was no treatment related mortality. Chemotherapy was completed in a median duration of 38.5 weeks. Administration of high dose methotrexate containing chemotherapy is feasible in pediatric patients with osteosarcoma, even in resource limited settings, if there are facilities for hydration, determination of methotrexate levels and good supportive care. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

41. Mucoepidermoid carcinoma of parotid gland as a subsequent neoplasm in children treated for acute lymphoblastic leukemia

Author

Nair, Reghu Sukumaran, Rajeswari, Binitha, Thankamony, Priyakumari, and Parukuttyamma, Kusumakumary

Subjects
Acute lymphocytic leukemia -- Complications and side effects -- Care and treatment, Salivary gland tumors -- Risk factors -- Diagnosis -- Care and treatment -- Patient outcomes -- Case studies, Health
Abstract

Byline: Reghu. Sukumaran Nair, Binitha. Rajeswari, Priyakumari. Thankamony, Kusumakumary. Parukuttyamma We report two cases of mucoepidermoid carcinoma occurring as a second neoplasm following treatment for acute lymphoblastic leukemia. Both patients [...]

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results